Literature DB >> 23104132

Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Sui Zhang1, Xiaobing Liu, Tasneem Bawa-Khalfe, Long-Sheng Lu, Yi Lisa Lyu, Leroy F Liu, Edward T H Yeh.   

Abstract

Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS). Here we show that cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation. Furthermore, cardiomyocyte-specific deletion of Top2b protects mice from the development of doxorubicin-induced progressive heart failure, suggesting that doxorubicin-induced cardiotoxicity is mediated by topoisomerase-IIβ in cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104132     DOI: 10.1038/nm.2919

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  24 in total

1.  Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta.

Authors:  Yi Lisa Lyu; James C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-28       Impact factor: 11.205

2.  A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.

Authors:  Bong-Gun Ju; Victoria V Lunyak; Valentina Perissi; Ivan Garcia-Bassets; David W Rose; Christopher K Glass; Michael G Rosenfeld
Journal:  Science       Date:  2006-06-23       Impact factor: 47.728

3.  DNA damage response and apoptosis.

Authors:  Dragos Plesca; Suparna Mazumder; Alexandru Almasan
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

4.  Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action.

Authors:  Jingxiong Wang; Sui Zhang; Brian Rabinovich; Luc Bidaut; Suren Soghomonyan; Mian M Alauddin; James A Bankson; Elizabeth Shpall; James T Willerson; Juri G Gelovani; Edward T H Yeh
Journal:  Circ Res       Date:  2010-05-06       Impact factor: 17.367

5.  A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.

Authors:  C Myers; R Bonow; S Palmeri; J Jenkins; B Corden; G Locker; J Doroshow; S Epstein
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

6.  Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.

Authors:  Yi Lisa Lyu; John E Kerrigan; Chao-Po Lin; Anna M Azarova; Yuan-Chin Tsai; Yi Ban; Leroy F Liu
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

7.  Isolation, culture, and functional analysis of adult mouse cardiomyocytes.

Authors:  Ronglih Liao; Mohit Jain
Journal:  Methods Mol Med       Date:  2007

8.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

9.  Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.

Authors:  Elke Martin; Annemette Vinding Thougaard; Morten Grauslund; Peter B Jensen; Fredrik Bjorkling; Brian B Hasinoff; Jette Tjørnelund; Maxwell Sehested; Lars H Jensen
Journal:  Toxicology       Date:  2008-10-25       Impact factor: 4.221

10.  Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.

Authors:  Tasneem Bawa-Khalfe; Jinke Cheng; Zhengxin Wang; Edward T H Yeh
Journal:  J Biol Chem       Date:  2007-10-11       Impact factor: 5.157

View more
  541 in total

Review 1.  Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training.

Authors:  Anthony F Yu; Lee W Jones
Journal:  Future Cardiol       Date:  2015-08-03

2.  Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?

Authors:  Ana Barac
Journal:  Future Cardiol       Date:  2015-08-04

3.  Anthracycline-induced cardiomyopathy: The search continues.

Authors:  Agnes S Kim; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2015-12-08       Impact factor: 5.952

Review 4.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

5.  Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers.

Authors:  Rajiv Panwar; Prashant Bhattarai; Vishwesh Patil; Keyur Gada; Stan Majewski; Ban An Khaw
Journal:  J Nucl Cardiol       Date:  2018-02-01       Impact factor: 5.952

Review 6.  Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.

Authors:  Jean Domercant; Nichole Polin; Eiman Jahangir
Journal:  Ochsner J       Date:  2016

7.  Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity.

Authors:  Fei Wang; Brian Iskra; Eugenie Kleinerman; Claudia Alvarez-Florez; Thomas Andrews; Angela Shaw; Joya Chandra; Keri Schadler; Gregory J Aune
Journal:  J Pediatr Hematol Oncol       Date:  2018-04       Impact factor: 1.289

8.  P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.

Authors:  Wuqiang Zhu; Wenjun Zhang; Weinian Shou; Loren J Field
Journal:  Cardiovasc Res       Date:  2014-05-08       Impact factor: 10.787

9.  Cardiac complications of chemotherapy: role of prevention.

Authors:  Laura Carola Magnano; Nuria Martínez Cibrian; Xavier Andrade González; Xavier Bosch
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

10.  The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations.

Authors:  Kamal Razavi-Azarkhiavi; Mahmoud Reza Jaafari; Khalil Abnous; Bibi Marjan Razavi; Amir Hossein Jafarian; Faezeh Vahdati Hassani; Kobra Shirani; Gholamreza Karimi
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.